Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27813648 | 0.90 | APLNR (0.51) | APLNRTAS1R3TAS1R1CA2CA12 | |
| SCHEMBL27813653 | 0.81 | APLNR (0.49) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL5334784 | 0.78 | IDO1 (0.55) | ALDH1A1MAPTTSHRNPSR1 | |
| SCHEMBL4003210 | 0.77 | APLNR (0.63) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL5998553 | 0.77 | APLNR (0.63) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL27621744 | 0.75 | APLNR (0.53) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL805138 | 0.75 | APLNR (0.66) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL31172821 | 0.75 | APLNR (0.66) | APLNRCA2CA12CA1CA7 | |
| SCHEMBL8865449 | 0.74 | APLNR (0.56) | APLNRTAS1R3TAS1R1HSD17B10MEN1 | |
| SCHEMBL19860802 | 0.74 | APLNR (0.51) | APLNRCA2CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235666-B2 | Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent | CILAG LTD. (CH) | 2007-06-26 | — | — | US | claimed |
| US-20050272706-A1 | Process for the preparation of sodium fosphenytoin | CILAG, LTD. | 2005-12-08 | — | — | US | claimed |
| US-7235666-B2 | Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent | CILAG LTD. (CH) | 2007-06-26 | — | — | US | disclosed |
| US-20050272706-A1 | Process for the preparation of sodium fosphenytoin | CILAG, LTD. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272706-A1 | Process for the preparation of sodium fosphenytoin | FOS, DUSP5, DCPS | APLNR 2523/4885TAS1R3 4595/4885TAS1R1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.